Discovery of a Novel DCAF1 Ligand Using a Drug-Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets.

Journal: Journal of chemical information and modeling
PMID:

Abstract

DCAF1 functions as a substrate recruitment subunit for the RING-type CRL4 and the HECT family EDVP E3 ubiquitin ligases. The WDR domain of DCAF1 serves as a binding platform for substrate proteins and is also targeted by HIV and SIV lentiviral adaptors to induce the ubiquitination and proteasomal degradation of antiviral host factors. It is therefore attractive both as a potential therapeutic target for the development of chemical inhibitors and as an E3 ligase that could be recruited by novel PROTACs for targeted protein degradation. In this study, we used a proteome-scale drug-target interaction prediction model, MatchMaker, combined with cheminformatics filtering and docking to identify ligands for the DCAF1 WDR domain. Biophysical screening and X-ray crystallographic studies of the predicted binders confirmed a selective ligand occupying the central cavity of the WDR domain. This study shows that artificial intelligence-enabled virtual screening methods can successfully be applied in the absence of previously known ligands.

Authors

  • Serah W Kimani
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Julie Owen
    Recursion Pharmaceuticals Inc., Toronto, Ontario M5V 2A2, Canada.
  • Stuart R Green
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Fengling Li
    Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Yanjun Li
    NSF Center for Big Learning, University of Florida, Gainesville, FL.
  • Aiping Dong
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Peter J Brown
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Suzanne Ackloo
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • David Kuter
    Department of Chemistry, McGill University, Montreal, H3A 0B8, Canada.
  • Cindy Yang
    Recursion Pharmaceuticals Inc., Toronto, Ontario M5V 2A2, Canada.
  • Miranda MacAskill
    Recursion Pharmaceuticals Inc., Toronto, Ontario M5V 2A2, Canada.
  • Stephen Scott MacKinnon
    Recursion Pharmaceuticals Inc., Toronto, Ontario M5V 2A2, Canada.
  • Cheryl H Arrowsmith
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Matthieu Schapira
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Vijay Shahani
    Recursion Pharmaceuticals Inc., Toronto, Ontario M5V 2A2, Canada.
  • Levon Halabelian
    Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.